Literature DB >> 20875295

Chemokine receptor 5 △32 allele in patients with severe pandemic (H1N1) 2009.

Yoav Keynan1, Jennifer Juno, Adrienne Meyers, T Blake Ball, Anand Kumar, Ethan Rubinstein, Keith R Fowke.   

Abstract

Because chemokine receptor 5 (CCR5) may have a role in pulmonary immune response, we explored whether patients with severe pandemic (H1N1) 2009 were more likely to carry the CCR5Δ32 allele than were members of the general population. We found a large proportion of heterozygosity for the CCR5Δ32 allele among white patients with severe disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20875295      PMCID: PMC3294998          DOI: 10.3201/eid1610.100108

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Chemokine receptor 5 (CCR5) is a protein that belongs to the β-chemokine receptor family and is expressed primarily on T cells, macrophages, and dendritic cells. CCR5 plays a role in mediating leukocyte chemotaxis in response to its ligands, which include RANTES, MIP-1a, and MIP-1b. It may help direct many immune cell subsets, including regulatory T cells and Th17 cells, to sites of infection. CCR5 is also 1 of 2 common co-receptors for HIV. Until recently, understanding the role of CCR5 in supporting the antiviral immune response was limited to appreciation of the role of receptor deficiency in protecting from HIV infection and disease progression. Persons who are homozygous for the CCR5Δ32 allele, a condition in which a 32-bp deletion in the CCR5 gene prevents its expression on the cell surface, have been shown to have reduced susceptibility to HIV infection; the heterozygous state delays HIV disease progression (–). However, homozygosity of the Δ32 allele has recently been shown to be associated with increased risk for symptomatic and fatal West Nile virus infection (). This association was confirmed in a larger meta-analysis (); CCR5 facilitated directed movement of lymphocytes during infection in a mouse model of West Nile virus infection (). A case report of an adverse reaction to the yellow fever virus vaccine in a person heterozygous for CCR5Δ32 and a link between the CCR5Δ32 allele and severe tickborne encephalitis symptoms suggest that CCR5 may play a role in the immune response to other flavivirus infections as well (,). Several reports have suggested a potential effect of the CCR5Δ32 allele on the response to influenza viruses. In mouse models, CCR5 is pivotal in directing CD8+ T cells to lung airways during challenge with Sendai virus (); similarly, deaths among CCR5–/– mice increase after infection with influenza A virus (). Because of the range of severity of recent pandemic (H1N1) 2009 infections and the possible role for CCR5 in the pulmonary immune response, we sought to determine whether patients requiring intensive care admission and respiratory support for severe pandemic (H1N1) 2009 were more likely to carry the CCR5Δ32 allele than were members of the general population.

The Study

In response to the outbreak of pandemic (H1N1) 2009 in Mexico, we conducted an observational study of critically ill patients with this infection in Winnipeg, Canada. The research was approved by the local research ethics board. The study protocol is described in detail (). We examined blood samples from 20 patients with laboratory-confirmed pandemic (H1N1) 2009. Average patient age was 40.35 years. Ethnicity was nonwhite for 10 patients, white for 9, and unknown for 1. Peripheral blood mononuclear cells were stored, and a subset of samples were thawed and resuspended in 200 uL phosphate-buffered saline. Genomic DNA was extracted by using the QIAamp DNA Mini Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer’s instructions. DNA was amplified by using previously reported primers surrounding the 32-bp deletion in the CCR5 gene: 5′ primer, TCATTACACCTGCAGCTCTC; 3′ primer, TGGTGAAGATAAGCCTCAC. Wild-type CCR5 DNA results in a 197-bp product, but the Δ32 allele results in a 165-bp product. The genotype was determined by visual examination of the PCR product and of a known heterozygote used as a control. The CCR5Δ32 allele was not found in the nonwhite patients, but it was found in 5 of the 9 white patients (Figure); overall allele frequency for white patients was 27.8%. Among the 5 who were heterozygous for the CCR5Δ32 allele, 1 died, 1 remained in the intensive care unit for >1 month, and 3 were discharged.
Figure

Amplification of the chemokine receptor 5 (CCR5) Δ32 locus in white patients. Lane 1, heterozygous positive control; lanes 2–5 and 7–11, patient samples; lane 6, 100-bp ladder; lane 12, negative control. CCR5Δ32 heterozygosity is observed in samples 2, 3, 4, 5, and 11.

Amplification of the chemokine receptor 5 (CCR5) Δ32 locus in white patients. Lane 1, heterozygous positive control; lanes 2–5 and 7–11, patient samples; lane 6, 100-bp ladder; lane 12, negative control. CCR5Δ32 heterozygosity is observed in samples 2, 3, 4, 5, and 11.

Conclusions

The outbreak of pandemic (H1N1) 2009 infection in Canada affected primarily young women; a preponderance were nonwhite and they had no major concurrent conditions. Risk factors identified included a history of lung disease or smoking, obesity, hypertension, and diabetes. The frequency of CCR5Δ32 heterozygosity among white populations has been reported to range from 10% to 15% (,); we found CCR5Δ32 heterozygosity at a higher than expected frequency (55.5%) among white patients with critical illness caused by pandemic (H1N1) 2009. Although deficiency of the receptor protects against acquisition of HIV, evidence is accumulating to suggest it plays a role in severity of illness caused by flavivirus infections (,). In animal models of influenza, CCR5 plays a role in directing CD8+ T cells to the site of infection, and its absence is associated with increased mortality rates (,); however, to our knowledge a similar association in humans has not yet been reported. Our observation suggests that CCR5Δ32 is 1 of the factors associated with increased severity of illness among white patients with pandemic (H1N1) 2009. Identifying genetic factors associated with greater risk for illness severity will help explain the unique pathogenesis displayed in the pandemic (H1N1) 2009 outbreak and may have public health implications. Further studies are required to illuminate the role of CCR5 in delivery of immune cells to the site of influenza infection.
  13 in total

1.  Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.

Authors:  R Liu; W A Paxton; S Choe; D Ceradini; S R Martin; R Horuk; M E MacDonald; H Stuhlmann; R A Koup; N R Landau
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

2.  Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus.

Authors:  T C Dawson; M A Beck; W A Kuziel; F Henderson; N Maeda
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

3.  Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.

Authors:  M Samson; F Libert; B J Doranz; J Rucker; C Liesnard; C M Farber; S Saragosti; C Lapoumeroulie; J Cognaux; C Forceille; G Muyldermans; C Verhofstede; G Burtonboy; M Georges; T Imai; S Rana; Y Yi; R J Smyth; R G Collman; R W Doms; G Vassart; M Parmentier
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

4.  Prevalence of chemokine and chemokine receptor polymorphisms in seroprevalent children with symptomatic HIV-1 infection in the United States.

Authors:  Kumud K Singh; Charlene F Barroga; Michael D Hughes; Jie Chen; Claire Raskino; Ross E McKinney; Stephen A Spector
Journal:  J Acquir Immune Defic Syndr       Date:  2004-03-01       Impact factor: 3.731

5.  Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.

Authors:  Bali Pulendran; Joseph Miller; Troy D Querec; Rama Akondy; Nelson Moseley; Oscar Laur; John Glidewell; Nathan Monson; Tuofu Zhu; Haiying Zhu; Sylvija Staprans; David Lee; Margo A Brinton; Andrey A Perelygin; Claudia Vellozzi; Philip Brachman; Susan Lalor; Dirk Teuwen; Rachel B Eidex; Marty Cetron; Frances Priddy; Carlos del Rio; John Altman; Rafi Ahmed
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

6.  Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic.

Authors:  Jean K Lim; Christine Y Louie; Carol Glaser; Cynthia Jean; Bernard Johnson; Hope Johnson; David H McDermott; Philip M Murphy
Journal:  J Infect Dis       Date:  2008-01-15       Impact factor: 5.226

7.  A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis.

Authors:  Elin Kindberg; Aukse Mickiene; Cecilia Ax; Britt Akerlind; Sirkka Vene; Lars Lindquist; Ake Lundkvist; Lennart Svensson
Journal:  J Infect Dis       Date:  2008-01-15       Impact factor: 5.226

8.  Critically ill patients with 2009 influenza A(H1N1) infection in Canada.

Authors:  Anand Kumar; Ryan Zarychanski; Ruxandra Pinto; Deborah J Cook; John Marshall; Jacques Lacroix; Tom Stelfox; Sean Bagshaw; Karen Choong; Francois Lamontagne; Alexis F Turgeon; Stephen Lapinsky; Stéphane P Ahern; Orla Smith; Faisal Siddiqui; Philippe Jouvet; Kosar Khwaja; Lauralyn McIntyre; Kusum Menon; Jamie Hutchison; David Hornstein; Ari Joffe; Francois Lauzier; Jeffrey Singh; Tim Karachi; Kim Wiebe; Kendiss Olafson; Clare Ramsey; Sat Sharma; Peter Dodek; Maureen Meade; Richard Hall; Robert A Fowler
Journal:  JAMA       Date:  2009-10-12       Impact factor: 56.272

9.  Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection.

Authors:  William G Glass; Jean K Lim; Rushina Cholera; Alexander G Pletnev; Ji-Liang Gao; Philip M Murphy
Journal:  J Exp Med       Date:  2005-10-17       Impact factor: 14.307

10.  CCR5 deficiency increases risk of symptomatic West Nile virus infection.

Authors:  William G Glass; David H McDermott; Jean K Lim; Sudkamon Lekhong; Shuk Fong Yu; William A Frank; John Pape; Ronald C Cheshier; Philip M Murphy
Journal:  J Exp Med       Date:  2006-01-17       Impact factor: 14.307

View more
  24 in total

1.  Cellular immune correlates of protection against symptomatic pandemic influenza.

Authors:  Saranya Sridhar; Shaima Begom; Alison Bermingham; Katja Hoschler; Walt Adamson; William Carman; Thomas Bean; Wendy Barclay; Jonathan J Deeks; Ajit Lalvani
Journal:  Nat Med       Date:  2013-09-22       Impact factor: 53.440

2.  Differences in the Epidemiology of Human Cases of Avian Influenza A(H7N9) and A(H5N1) Viruses Infection.

Authors:  Ying Qin; Peter W Horby; Tim K Tsang; Enfu Chen; Lidong Gao; Jianming Ou; Tran Hien Nguyen; Tran Nhu Duong; Viktor Gasimov; Luzhao Feng; Peng Wu; Hui Jiang; Xiang Ren; Zhibin Peng; Sa Li; Ming Li; Jiandong Zheng; Shelan Liu; Shixiong Hu; Rongtao Hong; Jeremy J Farrar; Gabriel M Leung; George F Gao; Benjamin J Cowling; Hongjie Yu
Journal:  Clin Infect Dis       Date:  2015-05-04       Impact factor: 9.079

3.  Meta- and Orthogonal Integration of Influenza "OMICs" Data Defines a Role for UBR4 in Virus Budding.

Authors:  Shashank Tripathi; Marie O Pohl; Yingyao Zhou; Ariel Rodriguez-Frandsen; Guojun Wang; David A Stein; Hong M Moulton; Paul DeJesus; Jianwei Che; Lubbertus C F Mulder; Emilio Yángüez; Dario Andenmatten; Lars Pache; Balaji Manicassamy; Randy A Albrecht; Maria G Gonzalez; Quy Nguyen; Abraham Brass; Stephen Elledge; Michael White; Sagi Shapira; Nir Hacohen; Alexander Karlas; Thomas F Meyer; Michael Shales; Andre Gatorano; Jeffrey R Johnson; Gwen Jang; Tasha Johnson; Erik Verschueren; Doug Sanders; Nevan Krogan; Megan Shaw; Renate König; Silke Stertz; Adolfo García-Sastre; Sumit K Chanda
Journal:  Cell Host Microbe       Date:  2015-12-09       Impact factor: 21.023

Review 4.  An updated systematic review of the role of host genetics in susceptibility to influenza.

Authors:  Peter Horby; Nhu Y Nguyen; Sarah J Dunstan; John Kenneth Baillie
Journal:  Influenza Other Respir Viruses       Date:  2013-09       Impact factor: 4.380

Review 5.  Host genetics of severe influenza: from mouse Mx1 to human IRF7.

Authors:  Michael J Ciancanelli; Laurent Abel; Shen-Ying Zhang; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2016-01-04       Impact factor: 7.486

Review 6.  Immunogenetic factors associated with severe respiratory illness caused by zoonotic H1N1 and H5N1 influenza viruses.

Authors:  Jennifer Juno; Keith R Fowke; Yoav Keynan
Journal:  Clin Dev Immunol       Date:  2011-11-03

7.  Editorial commentary: Host and viral factors in emergent influenza virus infections.

Authors:  David S Hui; Frederick G Hayden
Journal:  Clin Infect Dis       Date:  2014-01-31       Impact factor: 9.079

8.  Characterization in vitro and in vivo of a pandemic H1N1 influenza virus from a fatal case.

Authors:  Ariel Rodriguez; Ana Falcon; Maria Teresa Cuevas; Francisco Pozo; Susana Guerra; Blanca García-Barreno; Pamela Martinez-Orellana; Pilar Pérez-Breña; Maria Montoya; Jose Antonio Melero; Manuel Pizarro; Juan Ortin; Inmaculada Casas; Amelia Nieto
Journal:  PLoS One       Date:  2013-01-10       Impact factor: 3.240

9.  The CCR5Δ32 (rs333) polymorphism is not a predisposing factor for severe pandemic influenza in the Brazilian admixed population.

Authors:  Alvino Maestri; Mirleide Cordeiro dos Santos; Elzemar M Ribeiro-Rodrigues; Wyller Alencar de Mello; Rita Catarina Medeiros Sousa; Sidney Emanuel dos Santos; Vinicius Albuquerque Sortica
Journal:  BMC Res Notes       Date:  2015-07-30

10.  The CCR5Δ32 allele is not a major predisposing factor for severe H1N1pdm09 infection.

Authors:  Manuela Sironi; Rachele Cagliani; Chiara Pontremoli; Marianna Rossi; Guglielmo Migliorino; Mario Clerici; Andrea Gori
Journal:  BMC Res Notes       Date:  2014-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.